Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Building Indigenous people’s citizenship rights: the role of heritage

Oscar Espinoza Martin [2024] sees archaeology and cultural heritage as tools for strengthening Indigenous people’s sense of citizenship. “It is important how people feel about their past and how they navigate from there to the present,” he says. As an Indigenous person growing up in Lima with an early interest in history and philosophy, he […]

Scholar appointed VP of the Human Frontier Science Program

A former Gates Cambridge Scholar has been elected a Vice President of the Human Frontier Science Program (HFSP), an international programme funding excellent frontier research in the life sciences. Christian Boehm’s appointment was announced in late June at an event in Washington D.C. to celebrate the 35th anniversary of the HFSP. The programme, founded in […]

Inside Unit X

A Gates Cambridge Scholar has co-authored a book which gives an inside look at Unit X, the elite unit within the Pentagon that brings Silicon Valley’s cutting-edge technology to America’s military. Christopher Kirchhoff is co-author with Raj M Shah of Unit X: How the Pentagon and Silicon Valley Are Transforming the Future of War, published […]

Gates Cambridge welcomes new Interim Director

Dr Holly Tilbrook has been appointed Interim Director of Gates Cambridge. Currently Deputy Director in the Academic Centres Division at the University of Cambridge, Dr Tilbrook joins Gates Cambridge in August following a diverse career at the University of Cambridge. She describes herself as “the classic generalist administrator”. Starting in the Faculty of Classics in […]